Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 142,939 |
|
|||||
| News | - | ||||||
| Day High | 1.53 | Low High |
|||||
| Day Low | 1.42 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| NKGen Biotech Inc | NKGN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.08 | -5.30% | 1.43 | 18:54:36 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.45 | 1.42 | 1.53 | 1.46 | 1.51 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 882 | 142,939 | US$ 1.47 | US$ 209,771 | - | 0.7802 - 6.70 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:55:05 | 1 | US$ 1.50 | USD |
NKGen Biotech Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 31.96M | 21.89M | - | 0 | -82.95M | -3.79 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NKGen Biotech News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/22/2024 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/14/2024 | 19:19 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/14/2024 | 19:16 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/14/2024 | 19:14 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/14/2024 | 19:11 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/14/2024 | 12:05 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 1/22/2024 | 05:12 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/08/2024 | 16:19 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/28/2023 | 15:14 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/27/2023 | 15:02 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/27/2023 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/19/2023 | 12:41 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NKGN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.71 | 2.11 | 1.42 | 1.73 | 1,553,280 | -0.28 | -16.37% |
| 1 Month | 1.78 | 2.11 | 0.821 | 1.55 | 2,519,361 | -0.35 | -19.66% |
| 3 Months | 1.55 | 4.06 | 0.7802 | 1.85 | 3,872,141 | -0.12 | -7.74% |
| 6 Months | 3.00 | 4.06 | 0.7802 | 1.88 | 1,852,700 | -1.57 | -52.33% |
| 1 Year | 5.98 | 6.70 | 0.7802 | 1.93 | 1,627,848 | -4.55 | -76.09% |
| 3 Years | 5.98 | 6.70 | 0.7802 | 1.93 | 1,627,848 | -4.55 | -76.09% |
| 5 Years | 5.98 | 6.70 | 0.7802 | 1.93 | 1,627,848 | -4.55 | -76.09% |
NKGen Biotech Description
| NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in neurodegeneration and immune-oncology and are passionate and excited about the work we are doing to strengthen the immune system. |
